NEWS

NEWS

Total 77

77
Press Release NeoImmuneTech Presents Promising Interim Results of CAR-T Combination with its NT-I7 Asset at ESMO 2024
2024-09-09
76
Press Release NeoImmuneTech’s New Data at ASCO 2024 Highlights Enhanced Benefits of Combining NT-I7 with Checkpoint Inhibitors in Immuno-Oncology
2024-06-04
75
Press Release EMA Grants Orphan Drug Designation to NeoImmuneTech’s NT-I7 for the Treatment of Acute Radiation Syndrome
2024-06-04
74
Press Release NeoImmuneTech’s NT-I7 in Combination with Chemotherapy Shows Efficacy in Colorectal Cancer at AACR Meeting
2024-04-18
73
Press Release NeoImmuneTech Appoints Dr. Luke Oh, Ph.D. as New Chief Executive Officer
2024-04-03
72
Press Release FDA Grants Orphan Drug Designation (ODD) Status to NeoImmuneTech’s NT-I7 for Advanced Pancreatic Cancer Treatment
2024-01-30
71
Press Release NeoImmuneTech Welcomes a New President for its development and business
2024-01-15
70
Press Release NeoImmuneTech and Imugene enter into strategic research collaboration to improve cancer treatments
2023-12-12
69
Press Release FDA Grants Orphan Drug Designation to NeoImmuneTech’s NT-I7 for the Treatment of Acute Radiation Syndrome
2023-11-20
68
Press Release NeoImmuneTech to Present New Advances on NT-I7 (efineptakin alfa) at 2023 SITC Annual Meeting
2023-10-04

1 2 3 4 5 >>>